Progress in the Study of the Effect of Immune Checkpoint Inhibitors on Thyroid Function in Patients with Hepato-cellular Carcinoma
Immune checkpoint inhibitors(ICIs)that bring hope for survival to patients with intermediate-and advanced-stage hepatocellular carcinoma(HCC)are usually accompanied by the occurrence of immune-related adverse events(irAEs).Thyroid dysfunction(TD)is the most common endocrine-related adverse reaction of ICIs,whereas HCC patients are often comorbid with underlying liver diseases,such as cirrhosis,and may also develop TD,and the two may occur simultaneously in the same patient,contributing to each other and thus exacerbating disease progression.The study reviews the research progress on the impact of ICIs on thyroid function in HCC patients,summarizes the existing possible pathogenesis,clinical management,predictive biomarkers,and the impact on the prognosis of HCC patients.This will improve clinicians'knowledge of thyroid irAEs,characterize the treatment of HCC patients who develop thyroid irAEs,early monitoring,post-treatment follow-up,and mitigate the impact of irAEs on cancer patients.
Immune checkpoint inhibitorsImmune related adverse effectsThyroid dysfunctionHepatocellular carcinoma
NETL
NSTL
万方数据
维普
